Full Press Release Details
Pharmaceuticals Commences Human
Clinical Trials of an Oral GLP-1 Analog
is being developed as an oral dosage form of a GLP-1 Analog
improving glycemic control in adults with type 2 diabetes.
Israel - September 9, 2009 - Oramed Pharmaceuticals Inc. (OTCBB:
ORMP.OB), a developer of oral drug delivery systems, announced today that it has
received approval from the Institutional Review Board (IRB) to commence human
clinical trials of an oral GLP-1 Analog. This approval was granted after
successful pre-clinical results were reported. The trials will be conducted on
healthy volunteers at Hadassah University Medical Center in
all GLP-1 Analogs are only available as injections. The oral administration of
GLP-1 Analogs may convey physiological advantages for diabetic patients, as the
hormone mimics the physiological route of incretin absorption.
GLP-1 Analogs belongs to
the Incretin family of drugs which have pleiotropic effects desirable in the
management of diabetes. Among the more important effects are the
insulinotropic effects and resultant reduction in blood glucose levels, the
inhibition of glucagon secretion and the restoration of cell
mass. GLP-1 Analogs are also associated with weight loss, which is very desirable in
patients with diabetes.
from preclinical trials to human clinical trials of ORMD-0901 marks a strategic
milestone for the company. We have expanded our platform technology and will now
have the opportunity to demonstrate its effectiveness in another important
family of polypeptide drugs for diabetes, which is currently only available in
injection form," said Oramed CEO Nadav Kidron.
currently conducting Phase 2b clinical trials of its flagship product,
ORMD-0801, an oral insulin capsule.
Oramed Pharmaceuticals
Pharmaceuticals is a technology pioneer in the field of oral delivery solutions
for drugs and vaccines presently delivered via injection. Oramed is seeking
to revolutionize the treatment of diabetes through its patented flagship
product, an orally ingestible insulin capsule currently in phase 2 clinical
trials. Established in 2006, Oramed's technology is based on over 25 years of
research by top research scientists at Jerusalem's Hadassah Medical Center. The
Company's corporate and R&D headquarters are based in
For more information, please visit
the statements contained in this press release are forward-looking statements
which involve known and unknown risks, uncertainties and other factors which may
cause the actual results, performance or achievements of the company, or
industry results, to be materially different from any future results,
performance or achievements expressed or implied by such forward looking
statements, including the risks and uncertainties related to the progress,
timing, cost, and results of clinical trials and product development programs;
difficulties or delays in obtaining regulatory approval for our product
candidates; competition from other pharmaceutical or biotechnology companies;
and the company's ability to obtain additional funding required to conduct its
research, development and commercialization activities. Please refer to the
company's filings with the Securities and Exchange Commission for a
comprehensive list of risk factors that could cause actual results, performance
or achievements of the company to differ materially from those expressed or
implied in such forward looking statements. The company undertakes no obligation
to update or revise any forward-looking statements.
and Investor Relation Contacts:
Pharmaceuticals Inc.